Spruce biosciences to participate in the rbc capital markets global healthcare conference

San francisco--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that richard king, chief executive officer, will participate in a virtual fireside chat at the rbc capital markets global healthcare conference on may 19, 2021 at 5:25pm edt. interested parties can access the live webcast for the conference from the events section of the company’s investor relations website at https://investors.sprucebiosciences.com. an archived replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days. about spruce biosciences spruce biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (cah). classic cah is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (pcos) with primary adrenal androgen excess, representing 3-5% of females with pcos (estimated to be 150,000 to 200,000 patients in the united states). to learn more, visit www.sprucebiosciences.com and follow us on twitter @spruce_bio, linkedin, facebook and youtube.
SPRB Ratings Summary
SPRB Quant Ranking